Cleared Traditional

APRONS, SCRUBS SLACKS & TOPS, PATIENT DRAPE (K891212) - FDA 510(k) Clearance

Class I General Hospital device.

K891212 · Pro-Safe Professional Linens, Inc. · General Hospital
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 1989
Decision
38d
Days
Class 1
Risk

K891212 is an FDA 510(k) clearance for the APRONS, SCRUBS SLACKS & TOPS, PATIENT DRAPE. Classified as Suit, Surgical (product code FXO), Class I - General Controls.

Submitted by Pro-Safe Professional Linens, Inc. (Grand Junction, US). The FDA issued a Cleared decision on April 14, 1989 after a review of 38 days - a notably fast clearance cycle.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 878.4040 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Pro-Safe Professional Linens, Inc. devices

Submission Details

510(k) Number K891212 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 07, 1989
Decision Date April 14, 1989
Days to Decision 38 days
Submission Type Traditional
Review Panel General Hospital (HO)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
91d faster than avg
Panel avg: 129d · This submission: 38d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code FXO Suit, Surgical
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 878.4040
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.